GLP-1 Research Tracker

Every clinical trial and published study on semaglutide, tirzepatide, and next-generation GLP-1 medications — curated with plain-language summaries.

234 studies tracked·6 compounds covered·Updated Jul 2026

Has results

Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial.

retatrutide

Obesity pillarsDec 2025

Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.

semaglutidetirzepatideliraglutidesurvodutide

Hepatology (Baltimore, Md.)Dec 2025

Phase 2

Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.

retatrutide

Diabetes, obesity & metabolismDec 2025

Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.

survodutide

Diabetes, obesity & metabolismDec 2025

Phase 3

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.

orforglipron

The New England journal of medicineNov 2025

Phase 2

Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.

orforglipron

Diabetes, obesity & metabolismNov 2025

Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.

semaglutidetirzepatideliraglutidesurvodutideretatrutide

Obesity (Silver Spring, Md.)Nov 2025

Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta-Analysis.

orforglipron

Endocrinology, diabetes & metabolismNov 2025

Phase 2

Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids.

retatrutide

Diabetes, obesity & metabolismOct 2025

In early T2D inadequately controlled with diet and exercise, once-daily orforglipron reduced HbA vs. placebo at 40 wk.

orforglipron

Annals of internal medicineOct 2025

Phase 3

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.

orforglipron

The New England journal of medicineSep 2025

Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.

semaglutidetirzepatideliraglutidesurvodutideretatrutide

The Journal of clinical endocrinology and metabolismSep 2025

Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

semaglutidetirzepatideliraglutideretatrutide

Endocrinology, diabetes & metabolismSep 2025

Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis.

tirzepatideorforglipron

BMJ (Clinical research ed.)Aug 2025

Phase 2

Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.

retatrutide

The lancet. Diabetes & endocrinologyAug 2025

Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats.

semaglutidetirzepatideretatrutide

PsychopharmacologyJul 2025

Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.

retatrutide

Journal of basic and clinical physiology and pharmacologyJul 2025

Phase 2

Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes.

orforglipron

Cardiovascular diabetologyJun 2025

Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis.

semaglutideliraglutideorforglipron

Diabetes, obesity & metabolismApr 2025

Phase 2

Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.

survodutide

Diabetes, obesity & metabolismApr 2025

Load more studies →

GLP-1 Research Tracker

Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial.

Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.

Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study.

Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.

Orforglipron, an oral non-peptide glucagon-like peptide-1 receptor agonist, improves markers of β-cell function and insulin sensitivity in type 2 diabetes.

Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.

Efficacy and Safety of Orforglipron in Obese Adults With or Without Diabetes: A Systematic Review and Meta-Analysis.

Decreases in circulating ANGPTL3/8 concentrations following retatrutide treatment parallel reductions in serum lipids.

In early T2D inadequately controlled with diet and exercise, once-daily orforglipron reduced HbA vs. placebo at 40 wk.

Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.

Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis.

Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.

Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis.

Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.

Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats.

Efficacy and safety of retatrutide for the treatment of obesity: a systematic review of clinical trials.

Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes.

Comparison of the efficacy and safety of GLP-1 receptor agonists on cardiovascular events and risk factors: A review and network meta-analysis.

Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.

Get Weekly Research Updates